10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 2,388 Shares of Stock

10x Genomics, Inc. (NASDAQ:TXG – Get Rating) insider Benjamin J. Hindson sold 2,388 shares of the stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $55.06, for a total value of $131,483.28. Following the transaction, the insider now owns 284,236 shares in the company, valued at $15,650,034.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

10x Genomics Trading Down 2.9 %

Shares of NASDAQ:TXG opened at $51.24 on Friday. 10x Genomics, Inc. has a one year low of $23.81 and a one year high of $58.30. The business’s 50-day simple moving average is $52.58 and its 200 day simple moving average is $45.41.

10x Genomics (NASDAQ:TXG – Get Rating) last posted its quarterly earnings data on Wednesday, May 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.06). 10x Genomics had a negative return on equity of 22.02% and a negative net margin of 32.51%. The business had revenue of $134.29 million for the quarter, compared to analysts’ expectations of $128.87 million. During the same quarter in the prior year, the firm earned ($0.38) earnings per share. 10x Genomics’s revenue for the quarter was up 17.3% compared to the same quarter last year. On average, analysts expect that 10x Genomics, Inc. will post -1.39 earnings per share for the current year.

Institutional Investors Weigh In On 10x Genomics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its holdings in 10x Genomics by 75.5% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,349,229 shares of the company’s stock worth $66,907,000 after purchasing an additional 1,010,643 shares during the last quarter. Westpac Banking Corp bought a new stake in shares of 10x Genomics in the 3rd quarter valued at approximately $1,905,000. Credit Suisse AG increased its holdings in shares of 10x Genomics by 27.8% in the 3rd quarter. Credit Suisse AG now owns 2,154,964 shares of the company’s stock valued at $61,374,000 after acquiring an additional 468,207 shares during the last quarter. Abundance Wealth Counselors bought a new stake in shares of 10x Genomics in the 4th quarter valued at approximately $235,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of 10x Genomics by 1,290.2% in the 4th quarter. Russell Investments Group Ltd. now owns 30,278 shares of the company’s stock valued at $1,103,000 after acquiring an additional 28,100 shares during the last quarter. 74.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TXG. Morgan Stanley increased their target price on 10x Genomics from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday, February 16th. UBS Group started coverage on 10x Genomics in a research report on Thursday, February 2nd. They set a “neutral” rating and a $50.00 target price on the stock. Stifel Nicolaus raised their price objective on 10x Genomics from $57.00 to $68.00 in a report on Thursday, May 4th. Canaccord Genuity Group raised their price objective on 10x Genomics from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, February 16th. Finally, Cowen raised their price objective on 10x Genomics from $52.00 to $57.00 and gave the stock an “outperform” rating in a report on Thursday, February 16th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $54.85.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.